Supernus Pharmaceuticals (SUPN) Receives News Impact Score of 0.23
News articles about Supernus Pharmaceuticals (NASDAQ:SUPN) have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Supernus Pharmaceuticals earned a news sentiment score of 0.23 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 45.3794812365728 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- Supernus Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SUPN) : December 15, 2017 (finance.yahoo.com)
- Supernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SUPN-US : December 14, 2017 (finance.yahoo.com)
- Investor’s Roundup (Volatility in Focus) – Supernus Pharmaceuticals, Inc., (NASDAQ: SUPN) – Stock Watch (stocksnewstimes.com)
- Stocks Showing Improved Relative Strength: Supernus Pharmaceuticals (finance.yahoo.com)
- Stocks Generating Improved Relative Strength: Supernus Pharmaceuticals (finance.yahoo.com)
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) opened at $39.65 on Friday. The company has a market capitalization of $2,030.00, a price-to-earnings ratio of 37.74, a PEG ratio of 1.69 and a beta of 1.19. Supernus Pharmaceuticals has a 1 year low of $22.70 and a 1 year high of $50.04.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. The business had revenue of $80.40 million during the quarter, compared to the consensus estimate of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The company’s quarterly revenue was up 41.5% on a year-over-year basis. analysts predict that Supernus Pharmaceuticals will post 1.07 earnings per share for the current fiscal year.
A number of equities analysts have recently weighed in on the company. SunTrust Banks reissued a “buy” rating and issued a $61.00 price target on shares of Supernus Pharmaceuticals in a report on Friday, November 3rd. Cowen set a $50.00 price target on Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 23rd. Janney Montgomery Scott reissued a “hold” rating and issued a $47.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. B. Riley reissued a “buy” rating and issued a $50.00 price target on shares of Supernus Pharmaceuticals in a report on Monday, November 20th. Finally, Jefferies Group reissued a “buy” rating and issued a $51.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $49.60.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.